Ask AI
ProCE Banner Activity

Switching or Augmenting in MDD: Approaching the Next Step When First-line Treatments Fall Short

Clinical Thought

When first-line treatments for major depressive disorder fall short, healthcare professionals face a crucial choice: switch medications or augment the current regimen. This commentary outlines key considerations, from confirming the diagnosis to honoring patient preferences, to help guide that next step with confidence.

Released: August 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc. and Intra-Cellular Therapies, Inc.

AbbVie Inc.

Intra-Cellular Therapies, Inc.

Instructions for Credit

Primary Author

Joseph F. Goldberg, MD: consultant/advisor/speaker: AbbVie, Alkermes, Alvogen, Axsome, Bristol Myers Squibb, Genomind, Intra-Cellular, Neumora, Otsuka, Sunovion.